Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC

EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2

EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

Now Viewing

EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions

EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care

EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Video content above is prompted by the following:

What additional factors do you consider when determining the most effective sequence of these therapies (FTD/TPI plus bevacizumab, fruquintinib, regorafenib)?
What future research is needed to better understand the optimal sequencing of these therapies?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!